In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Avant and Celldex in $115mm merger

Executive Summary

Immunotherapeutics companies Avant and Celldex Therapeutics (majority-owned by Medarex) have agreed to merge in an all-stock deal worth about $115mm.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Intra-Biotech Deal
    • Payment Includes Stock
    • Includes Contract
    • Reverse Acquisition
    • Acquisition of Private Biotech

Related Companies

Advertisement
UsernamePublicRestriction

Register